SCHEMBL22843399

SCHEMBL22843399

CN(CP)S(=O)(=O)c1ccc(Nc2ccc(C(F)(F)F)cn2)c(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ TNNI3K Q59H18 1/20 0.42
▸ GAA P10253 3/20 0.40
▸ MAPK10 P53779 1/20 0.39
▸ TEAD1 P28347 1/20 0.39
▸ BRAF P15056 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ LIPE Q05469 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ PRKAB2 O43741 1/20 0.35
▸ PRKAG1 P54619 1/20 0.35
▸ PRKAA2 P54646 1/20 0.35
▸ PRKAA1 Q13131 1/20 0.35
▸ PRKAG3 Q9UGI9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22843417 0.91 KDM4E (0.37) MAPTKDM4EMEN1KMT2ATNNI3K
SCHEMBL22843427 0.88 KDM4E (0.41) MAPTKDM4EMEN1KMT2ATNNI3K
SCHEMBL22843472 0.87 KMT2A (0.38) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL22843410 0.85 TNNI3K (0.40) MAPTKDM4EMEN1KMT2ATNNI3K
SCHEMBL22718099 0.85 BMP1 (0.46) MAPTKDM4EMEN1KMT2AGAA
SCHEMBL22843415 0.84 CA2 (0.36) MAPTKDM4EMEN1KMT2ATNNI3K
SCHEMBL22843482 0.83 CCR6 (0.43) MAPTKDM4EMEN1KMT2ATNNI3K
SCHEMBL24501947 0.82 KDM4E (0.55) MAPTKDM4EMEN1KMT2ATNNI3K
SCHEMBL22843501 0.81 IDH1 (0.41) CCR6CCNKCCNA2CDK2CDK12
SCHEMBL22843409 0.81 CYP2C9 (0.37) MAPTKDM4EMEN1KMT2ATNNI3K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 MAPT 507/4885KDM4E 972/4885MEN1 3307/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 MAPT 507/4885KDM4E 972/4885MEN1 3307/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 MAPT 507/4885KDM4E 972/4885MEN1 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback